A Beat Built Below the Line: Compressing Margins and a Stalled Medicaid Trough Sink the Stock 8.5% — Downgrade to Hold

Results vs. Consensus

Year-Over-Year Comparisons

The pairing that defines the quarter sits in two rows: adjusted EPS down 15.7% while net investment income jumped 44.9%. The insurance business earned less; the investment portfolio earned more; and the portfolio's windfall is what put the headline above consensus. Revenue growth of 0.8% reflects the deliberate membership contraction (MA and Medicaid exits) offsetting premium yield, the expected signature of a repositioning trough year.

Quarter-Over-Quarter Comparisons

Q2 sits below Q1 by design: deductibles have partly reset, claims build, and the MLR steps up seasonally. Management guided Q1 to ~46.6% of the full year and Q2 to ~27.6%, then flagged Q3 at only ~17% (implying ~9% for Q4). That back-half compression is not just seasonality this year: it also reflects the $0.80 of one-time investment spend landing in H2, which is why the shape looks steeper than a normal ELV cadence.

Quality of Beat/Miss

• EPS: Low quality, for the second consecutive quarter. Of the reported $7.45, ~$0.80 is a non-recurring net-investment-income valuation gain that does not reflect insurance operations and is being redeployed, not retained. The durable operating beat versus consensus was ~$0.44, and even that leaned on the higher-margin lines (MA, ACA) while Health Benefits operating gain fell ~43% year-over-year.
• Margins: The clear negative. The consolidated benefit ratio rose 80bps YoY to 89.7% on elevated government-plan costs, operating margin compressed 140bps to 3.5%, and adjusted operating margin fell to 3.6% from 5.0%. Rising MLR in a raised-guidance quarter is the tension the market fixated on: it reads as pricing power that has not yet caught trend.
• Guidance: The $0.25 headline raise (to ≥$27.00) is essentially the same modest, honest step the clean baseline took: the 2027 modeling baseline moved up $0.25 to ≥$26.00. The $0.80 windfall was explicitly excluded from that baseline. Directionally positive, but a fifth of the size the "$27 guide" optics suggest, and the operating-margin trajectory undercuts confidence in the slope beyond the number.

The $0.80 Windfall, and Why Spending It Rattled the Street

Assessment: There is a generous reading and a skeptical one, and the market chose the skeptical one. The generous reading: management is matching a one-time gain to one-time capability investment, refusing to inflate the run-rate, and pulling forward spend that accelerates the 2027 operating-leverage story. That is genuinely disciplined behavior, and it is consistent with the credibility-rebuilding posture we praised at Q1. The skeptical reading: a managed-care company that takes an investment windfall and immediately spends all of it on "medical cost management" is signaling that it sees cost pressures it needs to get ahead of, and is using a non-operating gain to pre-fund that defense while smoothing the optics. When the same company holds its Medicaid margin flat despite better rates and announces market exits in the same breath, the skeptical reading wins. The behavior is defensible; the timing of it, against a deteriorating operating-margin line, is what the 8.5% drop is about.

The CMS $935M Matter — Resolved and Closed

Assessment: This is exactly the clean resolution we said we needed when we held the item as a watch, not a rating driver, at Q1. It removes a genuine tail risk (risk-adjustment integrity matters can metastasize; this one did not), converts an accrual into a bounded cash outflow, and clears the MA franchise for the 2027 selling season. That it barely registered in the tape tells you everything about where the market's attention was: the overhang cleared, and the stock fell anyway, because the operating quarter, not the regulatory one, was the problem.

Segment Performance

Medicaid — the trough holds, but the exit door opened

Medicaid is where the thesis got harder. Second-quarter cost trend developed "broadly in line" with the framework, but the drivers management has named for a year (behavioral health including ABA therapy, emergency-department utilization, outpatient surgery, specialty pharmacy) remain elevated, and July rate updates came in "better than expected," toward the upper end of a mid-single-digit range. The problem is what those two facts do not produce: any improvement in the full-year margin. Management held -1.75% unchanged, characterizing the outlook as "appropriately prudent," because the better rates are being absorbed by the persistent utilization. Then it opened a new front: a mutual agreement to exit D.C. Medicaid, and a stated intent to exit "additional Medicaid markets over the next 12-18 months" where there is no path to sustainable performance.

"Rate updates received during the quarter were higher than anticipated, and membership and acuity remain broadly aligned with our expectations... Taken together, our full-year Medicaid operating margin outlook of approximately -1.75% remains appropriately prudent based on what we see today." — Mark Kaye, CFO

Management's framing of the acuity dynamic was more constructive: the post-PHE reset, where healthy members exited and left a sicker residual pool, is "moderating," and the members leaving Medicaid today are "still lower cost than those that are staying" but by a gap that has "significantly narrowed." The incremental pressure is now utilization among continuing members, which management argues is more actionable than an acuity reset.

Assessment: The -1.75% trough level is holding, which preserves the floor of the recovery thesis. But the slope out of the trough is now the open question, and this quarter widened it rather than narrowing it. Better rates that do not lift the margin mean trend is running with the rate, and a company that has to prune markets to fix Medicaid economics is telling you that pricing alone will not do it. The acuity-moderation commentary is a real positive for 2027, but the exits are a strategic admission that parts of this book are structurally, not just cyclically, unprofitable. This is the single most important negative in the print for the multi-year case.

Medicare Advantage — the portfolio surgery is working

MA was the clearest bright spot and the larger half of the operating beat. The deliberate 2026 portfolio actions (market and plan exits, a tighter D-SNP and HMO mix, disciplined benefit design) are translating into favorable claims experience and keep the path to a ≥2% operating margin on track. MA membership is down ~15.9% year-over-year to roughly 1.9M, but that shrinkage is the strategy: management traded volume for sustainable economics. The 2027 bids were submitted with the same discipline and a prudent view that medical cost trend still outpaces program funding, even after the firmer final 2027 rate.

"The intentional portfolio actions we took for 2026 are translating to improved performance. Disciplined plan design, a more focused product mix, favorable claims experience, and our capabilities all support our path to an operating margin of at least 2% this year." — Mark Kaye, CFO

Assessment: MA is doing exactly what the recovery needs: proving that a repositioned book can restore margin even in a tight funding environment. It is the strongest evidence in the quarter that management's self-help toolkit works when it controls the levers (mix, design, plan footprint). The read-through to Medicaid is pointed, though: MA fixed its margin by shrinking and repositioning, and Medicaid is now being sent down the same path. That validates the playbook and concedes that Medicaid's fix is multi-year and volume-negative.

Individual ACA — favorable, but deliberately not banked

ACA delivered the other half of the operating beat, driven by the pronounced seasonality of a higher bronze mix and by favorable final 2025 CMS risk-adjustment results that came in ahead of ELV's prior estimate. Management pointedly declined to extrapolate: it re-established the "vast majority" of that 2025 favorability into the current-year risk-adjustment accrual, citing changed member mix, the bronze shift's implications for premium yield, and still-maturing claims. Retention is running modestly ahead of plan; year-end membership guidance was raised to at least 1.0M.

"We are prudently reestablishing the majority of the prior year favorability in our current year risk adjustment accrual given current market dynamics, member mix, and claims experience that is still maturing." — Mark Kaye, CFO

Assessment: This is high-integrity accounting and also a tell about conviction. Booking favorable risk-adjustment results and then re-accruing most of them is the opposite of the earnings management the bears fear, and it protects the back half from an ACA reversal. But re-accruing rather than banking real favorability also says management is not yet confident enough in the ACA risk pool to let it drop through. Working, but held at arm's length, which is the right posture into an uncertain 2027 subsidy and enrollment environment.

Commercial / ASO — the quiet ballast

Commercial developed in line, with elevated but priced-for trend and continued pricing discipline. The forward story is the strength: 2026 was a record year in national accounts, and the 2027 pipeline came back "almost just as large," with persistency and sale rates climbing and a notable pattern of clients who left two or three years ago returning to Anthem. The integrated medical-and-pharmacy model, aimed squarely at the market's affordability-and-simplicity obsession, is the pull.

"One of our big opportunities this year was customers that left us two or three years ago in the middle of their contract with an alternative payer have moved back to Anthem. That's something that... speaks loudly... about the quality of the assets." — Morgan Kendrick, President, Commercial Health Benefits

Assessment: Commercial and ASO are the fee-based, capital-light, sticky leg of the 2027 bridge that does not depend on government rate cycles, and the win-backs are a genuine competitive-position signal. It will not move the needle enough to offset a stalled Medicaid slope on its own, but it is the part of the portfolio that quietly de-risks the "diversified, not single-line-dependent" 2027 claim management leaned on all call.

Carelon — scaling, and back-loaded

Carelon performance was consistent with the full-year outlook, with CarelonRx seeing early 2027 selling-season traction on the integrated offer and Carelon Services in an investment-and-scaling phase that suppresses near-term earnings. Management leaned on proof points: behavioral-health programs delivering ~10% average cost savings, and CareBridge generating mid-teens medical savings as it extends the whole-health model into the home, now expanding to new markets.

"CareBridge extends Carelon's whole health model into the home, where better coordination can improve outcomes and lower costs. CareBridge can generate medical savings in the mid-teens for these members, and we're expanding it to new markets." — Gail Boudreaux, President and CEO

Assessment: Carelon remains the structural growth engine and the differentiator versus pure payers, and the risk-based programs bend cost rather than shift it. The near-term earnings are back-loaded by the scaling investment, so it is more a 2027-plus contributor than a Q2 needle-mover. Unchanged as a pillar, but not the swing factor this quarter.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Confident on the enterprise, and unusually insistent that the story does not hinge on any single line of business, an insistence that itself signaled where the pressure sits. Management was measured and process-oriented on Medicaid, repeatedly using the word "prudent," and leaned hard on the diversification of the 2027 bridge whenever the questioning circled the Medicaid margin. The posture on the $0.80 windfall and the H2 investment spend was proactive and transparent, but the framing shifted from Q1's "the actions are showing through in the results" to Q2's "we are investing to make performance more durable," a subtle move from demonstrating traction to defending it. The single most defensive moment was the reluctance to lift the Medicaid margin despite better rates, which management would only characterize as improving "over time."

1. The Beat Was Below the Line

Management opened by carving the quarter into its parts: ~$0.50 of operating outperformance (split roughly evenly between MA and ACA) and a separate ~$0.80 of net below-the-line investment gains earmarked for one-time H2 investment. The transparency was real, but so was the message: the number that beat consensus was not an operating number.

"In the quarter, we also recorded a net below-the-line benefit of $0.80 per share, primarily related to valuation adjustments within net investment income. Importantly, we intend to use this non-recurring benefit to fund one-time investments in the second half of the year." — Mark Kaye, CFO

Assessment: Crediting management for candor and debiting it for quality are not in tension. It told investors precisely what the beat was made of, which is the behavior of a team rebuilding trust; but what the beat was made of was portfolio marks, not underwriting. Two quarters running, the headline has been flattered by non-operating items, and the market has stopped giving the headline the benefit of the doubt.

2. Medicaid: Better Rates, Same Margin

The dominant topic of the call, by volume, was the disconnect between "rates came in better" and "margin is unchanged." Management's answer was that the July rate improvement is real but naturally moderated by timing and the affected portion of the book, and that it is staying deliberately prudent by not assuming a material back-half trend improvement.

"We are not assuming a material improvement in Medicaid trend in the back half of the year. The way I'd summarize it is as follows: elevated but understood trend, improving rate alignment, targeted cost actions underway, and a full-year margin outlook that we believe is appropriately prudent." — Mark Kaye, CFO

Assessment: "Elevated but understood" is the honest summary, and it is not the same as "improving." Holding -1.75% is prudent, but prudence that persists through a better rate cycle is indistinguishable, from the outside, from a margin that simply cannot yet move. Until a rate cycle actually lifts the margin, the trough is a floor, not a launch pad, and the market repriced accordingly.

3. Exiting Medicaid Markets

Management framed the D.C. exit and the coming 12-18 months of additional exits as portfolio discipline, the same market-by-market review it ran in Medicare last year, judging each state on strategic fit, operational fit, alignment to the dual footprint, and return on capital. It declined to size the exits against the ~$57B Medicaid revenue run-rate.

"We regularly assess each market based on strategic fit, operational requirements, and the ability to generate an appropriate return on capital... we expect to exit additional Medicaid markets over the next 12-18 months where we do not see a path to sustainable performance." — Gail Boudreaux, President and CEO

Assessment: Pruning unprofitable business is the right long-run move and mirrors the MA surgery that is now paying off. But announcing it in a quarter when rates improved and the margin did not is a loud signal that the Medicaid recovery runs through footprint reduction, not just rate catch-up. It should improve the quality of the remaining book over time; in the near term it caps Medicaid revenue and confirms the segment's fix is structural and slow.

4. The Investment Spend and 2027 Leverage

Pressed on what the one-time and recurring investments actually buy, management detailed capability-building aimed at the operating levers: compressing medical-cost-trend detection "from months to days," Sydney Health reaching ~22M members, Health OS pushing prior-auth toward 80% real-time and cutting avoidable denials, and Carelon value-based expansion. The claim is that these mature into 2027 operating leverage, in the medical-cost line, not just the admin line.

"We expect to see it in our medical cost structure, that's what these investments in medical management are about... it gives us the leverage that we're talking about." — Gail Boudreaux, President and CEO

Assessment: The distinction management drew, that the payoff shows up in medical costs and not merely SG&A, is the right one, because the 2027 ≥12% bridge needs MLR leverage, not just expense leverage. The proof points (denial reduction, detection speed) are concrete. The risk is timing and attribution: capability spend is easy to fund from a windfall and hard to hold accountable, and "it matures next year" is a promise the 2027 print will have to keep.

5. Medicare Advantage Is the Template

MA is doing what the recovery needs a segment to do: restoring margin through deliberate repositioning even against funding that trails trend. Management tied the ≥2% path directly to the 2026 portfolio actions and carried the same discipline into the 2027 bids, prioritizing sustainable-value plans and dual-eligible members over growth.

"We remain on track to achieve at least 2% margin for Medicare Advantage this year, and that gives us a fair amount of confidence that the strategy is working and has informed how we approach our 2027 bids." — Aimée Dailey, President, Government Health Benefits

Assessment: This is the quarter's best evidence that the self-help thesis is real, and it is why the print is a Hold and not something more negative. The playbook works. The uncomfortable corollary is that it works by shrinking, and Medicaid is next in line for the same treatment, which means the enterprise recovery is more about margin-through-contraction than growth-through-recovery.

6. Commercial's Near-Record 2027 Pipeline

Commercial supplied the most upbeat commentary: a 2027 national-account pipeline nearly matching a record 2026, rising persistency and sale rates, and clients returning after leaving for alternative payers. The integrated medical-and-pharmacy model is resonating with an employer base fixated on affordability and navigation.

"2026 was a record year in our national account business. Our pipeline came back almost just as large this year for the 2027 business... People vote with their feet." — Morgan Kendrick, President, Commercial Health Benefits

Assessment: The non-rate, fee-heavy leg of the 2027 bridge is strengthening, and the win-backs are a real competitive signal in a market where switching is rare. It is the least-discussed and most-dependable piece of the diversified-recovery claim, and it does genuine work in supporting the ≥12% algorithm without leaning on government rate cycles.

7. OBBBA and 2027 Medicaid Macro

Asked to reconcile "2026 is the trough" against the coming OBBBA package (work/community-engagement and verification requirements, SDP reform, 1115 waiver changes), management argued the macro is manageable and phased, not a second post-PHE unwind. It expects some incremental 2027 acuity pressure from eligibility dynamics but no broad-based reset, with the impacted population roughly 20% of the Medicaid book.

"We don't view that as a broad-based reset, anything comparable to the post PHE unwind. That's really significant because... the acuity shift to a large degree is behind us." — Mark Kaye, CFO

Assessment: The "acuity shift is largely behind us" claim is important and, if right, supports the trough call. But it sits awkwardly next to a margin that would not lift on better rates and a decision to exit markets: if the macro is manageable and acuity is settling, the burden is on 2027 to actually show the Medicaid margin inflecting. Management is asking for patience on the segment where it has the least visible control.

8. The 2027 ≥12% Bridge, Reaffirmed Off a Higher Base

Management reaffirmed ≥12% adjusted-EPS growth in 2027, now off a higher ≥$26.00 baseline, and repeatedly stressed the bridge is diversified across MA, commercial, Carelon, maturing investments, operating efficiency, and capital deployment rather than dependent on Medicaid recovery.

"Our path to at least 12% adjusted EPS growth in 2027 [is] broad-based, balanced, and grounded in execution across our businesses... It's not based on any one single line of business or one recovery assumption." — Mark Kaye, CFO

Assessment: The baseline ticking to ≥$26 (from $25.75) is a second consecutive positive revision and pushes the 2027 target to ≥$29.12. The diversification framing is credible, MA, commercial, and Carelon can carry the bridge with Medicaid merely stable. But the more management insists 2027 does not depend on Medicaid, the more it concedes Medicaid is a problem it cannot yet solve, and the bridge now rests more on capability-spend maturing and portfolio contraction than on a genuine cyclical recovery.

Analyst Q&A Highlights

Better rates, no margin lift, and a decision to exit states

The most direct challenge of the call put the central tension to management plainly: if Medicaid rates are improving and everything else is in line, why is there no margin lift, and why is the company talking more about exiting states now than it was a couple of years ago? The pushback captured exactly what unsettled the market, and management's answer confirmed that rate gains are being offset by utilization and that the exits are a deliberate, long-horizon portfolio decision rather than a rate-driven one.

Q: "You said rates are coming in better, and it seems like everything else is coming in line, but you haven't improved your outlook for margin. Why isn't there a lift if rates are coming in better? If rates are coming in better, why are we talking more about exiting potential states today than we have a couple of years ago? It seems like it's the opposite of an improving rate outlook."
— Kevin Fischbeck, Bank of America

A: "Our second half Medicaid trend outlook is very consistent with our first half experience and, in a sense, quite prudent... the July rate activity was favorable... though the full-year benefit is obviously naturally moderated by the timing and the portion of the book that's affected... we continue to see elevated utilization... you could think about [the July 1st rate update] still being in that mid-single digit percent range, maybe towards the upper end." — Mark Kaye, CFO

Assessment: Management did not really close the gap the question opened. Better rates that do not move the margin, paired with market exits, is the definition of trend running with rate, and the answer amounted to "prudent, and it improves over time." That is the exchange the 8.5% selloff was built on.

Does the Medicaid margin improve in the second half, and how large are the exits?

The opening question of the call asked for the intra-year Medicaid margin trajectory and any sizing of the market exits. Management confirmed a modestly better second-half margin profile on the July rates, but declined to quantify the exits, framing them as a long-term portfolio judgment rather than a near-term earnings lever.

Q: "That -1.75% margin, is the back half more favorable than the front half?... can you give us a sense of overall sizing maybe of how much we're talking about [on exits], and is this in any way driven by future things like work requirements, or is it basically driven by just current discussions with states?"
— A.J. Rice, UBS

A: "We do expect the second-half Medicaid margin profile to improve from the second quarter, and that's going to be supported by that favorable July 1st rate activity, as well as our continued execution against the cost pressures that we've been discussing." — Mark Kaye, CFO

Assessment: A modest back-half improvement off a low Q2 base, with the exits explicitly not a 2026 lever, is a "wait for it" answer. It keeps the full-year -1.75% intact but offers no reason to underwrite a steeper recovery slope than the guide already contains.

The seasonal favorability grew, and whether it reverses

An analyst pressed on why the first-half seasonal favorability increased sequentially (from ~$0.15 in Q1 to ~$0.25 in Q2) even as visibility improved, and whether the first-half upside reverses in the back half. Management reframed the beat as ~$0.50 of operating outperformance split between MA and ACA, tied the ACA half to bronze seasonality plus favorable 2025 risk adjustment, and cast the non-extrapolation as prudence rather than an expected reversal.

Q: "You called out $0.25 of favorability this quarter, which grew sequentially from $0.15 in the first quarter... can you help us understand why this increased sequentially?... is [there] anything you're seeing that suggests that this first half upside would reverse in the back half of the year, or is that just a conservative stance on your end?"
— Andrew Mok, Barclays

A: "In the quarter, we had about $0.50 of operating outperformance... about equally split between Medicare Advantage and the individual ACA... As we think about the outlook for the full-year, this is really about us being prudent for the second half rather than anything else." — Mark Kaye, CFO

Assessment: The decomposition was clean and the "prudence, not reversal" framing is credible, but it also means management is refusing to bank first-half favorability. For a low-quality-beat quarter, that conservatism is the right instinct, and it keeps the back half from being an air pocket, but it caps the upside case too.

Whether the $0.80 comes back to the bottom line in 2027

A pointed modeling question sought to nail down the mechanics of the investment spend: do the dollars come out next year and return $0.80 to EPS, or do they simply not recur and fall into the baseline? Management drew the line sharply: the ~$0.75 of already-planned investment is part of the ongoing run rate, while the ~$0.80 below-the-line redeployment is one-time and explicitly outside the 2027 baseline.

Q: "On the non-recurrence of the investment scale... Does that mean the dollars come out next year, i.e., $0.80 worth of EPS comes back to the bottom line next year, or you just don't grow those investments next year and they fall into the baseline?"
— Dave Windley, Jefferies

A: "The 2026 outlook from the first quarter already included approximately $0.75 of EPS tied to those targeted investment spending... Those investments should be viewed as part of the ongoing run rate... In addition... we now expect to deploy approximately $0.80 of net below the line favorability from the second quarter into one-time accelerated investments... You should not see that $0.80... as a recurring part. Those are one-time for this year, not part of 2027." — Mark Kaye, CFO

Assessment: The answer protects the 2027 baseline (the $0.80 is neither a recurring gain nor a recurring cost) and reinforces the ≥$26 jumping-off point. It is internally consistent and disciplined, but it also confirms that the reported $7.45 overstates run-rate earnings power, which is precisely the point the market docked the stock for.

What the one-time investments actually return

A question probed the operational leverage the investments buy, whether they are technology or people, and how to think about the 2027 return. Management characterized them as durable capability-building across medical-cost management, member experience, provider connectivity, and Carelon, with the payoff appearing in both the expense and, importantly, the medical-cost structure next year.

Q: "Can you help me understand how that's going to play into the growth rate going into next year, what kind of operational leverage you can get?... are these investments in technology and people?... what the return will be as we get into 2027?"
— Lisa Gill, JPMorgan

A: "Some are technology, but honestly, they're all driven based on improving the capabilities that we have inside of the business... It's not just going to be in our cost structure, our expense cost structure. We expect to see it in our medical cost structure, that's what these investments in medical management are about." — Gail Boudreaux, President and CEO

Assessment: Directing the payoff at the medical-cost line is the right answer for a 2027 bridge that needs MLR leverage, and the specificity (detection speed, denial reduction) is more than hand-waving. But it is a promissory note: the return is asserted for next year, unquantified, and funded by a windfall, which makes it the easiest part of the bridge to claim and the hardest to verify.

Acuity of Medicaid leavers and the embedded margin assumption

A recurring line of questioning probed whether continued Medicaid attrition is skewing the risk pool by shedding lower-utilizing members, and how much acuity pressure sits inside the -1.75% margin. Management said the healthy-leaver dynamic is moderating (the acuity gap between leavers and stayers has "significantly narrowed") and that the incremental pressure is increasingly utilization among continuing members, which it argues is more actionable.

Q: "You had one of the more conservative assumptions on acuity impact to trend this year... as Medicaid lives keep attriting, are you seeing the acuity of those members... continuing to tick higher, meaning the healthier members that keep attriting, is it kind of in line with that 2%-3%?"
— Justin Lake, Wolfe Research

A: "We are not seeing a new stepwise acuity reset. Membership and acuity remain broadly aligned with our assumptions, and the incremental pressure is increasingly coming from utilization among members who remain in the program. That distinction is really important because it gives us very clear operating levers." — Mark Kaye, CFO

Assessment: "No new stepwise acuity reset" is a genuinely constructive data point, and the shift from acuity-driven to utilization-driven pressure is a better problem to have because it is more addressable. But "addressable" is not "addressed": the margin still did not move, so the operating levers remain a 2027 story rather than a Q2 result.

Framing 2027 against the long-term algorithm

The closing question asked management to sketch the 2027 puts and takes against the long-term growth algorithm, segment by segment. Management declined to quantify but laid out the shape: Medicaid improving (not flat), MA benefiting from portfolio actions, commercial strong on sales, ACA priced consistently, and capital deployment contributing, all reaffirming the ≥12% path off the higher baseline.

Q: "Could you just quickly address where your early expectations and the puts and takes are for 2027, put against the long-term growth algorithm?... broadly sketching out the 2027 outlook versus the long-term growth algorithm."
— George Hill, Deutsche Bank

A: "On Medicaid, certainly our base case is not that the business remains flat. We do expect performance to improve, especially as rates increasingly reflect cost experience and as our key management actions mature... our path to at least 12% adjusted EPS growth in 2027, broad-based, balanced, and grounded in execution." — Mark Kaye, CFO

Assessment: The "Medicaid improves, not flat" commitment is the forward promise to watch, and it now carries more weight because Q2 gave no evidence of it yet. The bridge is coherent and diversified, but after a quarter that leaned on portfolio marks and refused to lift the troubled segment's margin, it is a bridge the 2027 prints will have to build, not just describe.

What They're NOT Saying

1. That the operating business went backward. The call led with "$27 guidance" and "diversified execution"; it did not lead with operating gain down ~28% year-over-year, Health Benefits operating gain down ~43%, or operating margin compressing 140bps. The headline points up; the operating trajectory points down.
2. Why better Medicaid rates produced no margin improvement. Management confirmed July rates beat expectations and held the margin flat, but never squarely reconciled the two beyond "prudence" and "elevated utilization." The unstated implication is that trend is still running at or above the improved rate.
3. The size of the Medicaid exits. Repeatedly asked to quantify the D.C.-plus-more exits against the ~$57B Medicaid run-rate, management declined. Investors cannot yet size the revenue or margin impact of a multi-market retreat.
4. That the $0.80 is funding trend defense, not just growth capability. The investment spend is framed as durable capability-building for long-term leverage; the first-named target every time is "medical cost management." Spending a windfall to get ahead of cost trend is a more defensive act than the "invest for growth" framing suggests.
5. How much of the reported $7.45 is run-rate. Management protected the 2027 baseline at ≥$26 but never volunteered the plain translation: the reported quarter overstates run-rate earnings power by roughly $0.80, and the "beat" versus consensus was mostly non-operating.

Market Reaction

• Pre-print setup: ELV closed at $426.79 on July 14, a 52-week closing high, having run +21.7% YTD and +26.9% over the trailing twelve months, within a $274.66-$426.79 52-week range. The stock entered the print priced for a clean beat-and-raise after a strong recovery re-rate.
• Reaction-day move: ELV gapped down 8.0% at the open ($392.78) and traded as low as $376.16 (-11.9%) before closing at $390.33, down 8.5% (-$36.46) on ~2.3x normal volume (3.9M vs. a 1.7M 30-day average). The S&P 500 closed +0.4%, so ELV lagged the tape by roughly nine points, and managed-care peers traded lower in sympathy on the margin-pressure read-through.
• Where it sits: The $390.33 close leaves ELV at ~14.5x the raised ≥$27.00 guide, ~15x the ≥$26.00 baseline, and ~13.4x a ≥$29.12 2027 number, back inside the recovery-multiple band it occupied before the spring rally.

The 8.5% drop is the market re-pricing a stock that had gotten ahead of itself. Into a 52-week high, the bar was a high-quality beat that lifted the operating trajectory; what arrived was a portfolio-mark beat on top of a compressing operating margin, a Medicaid margin that would not move despite better rates, and a fresh market-exit program. The clean CMS resolution, a genuine positive, was simply overwhelmed. This was not a thesis-breaking quarter, the recovery legs (MA, commercial, Carelon, higher baseline) are intact, but it was a quality-and-slope-questioning quarter delivered at exactly the price that could least afford one. The stock did not fall because the business is broken; it fell because it was priced for a better version of this quarter than the one it got.

Street Perspective

Debate: Was this a beat or a miss?

Bull view: A 20% headline beat and a guidance raise are a beat, full stop; even ex the $0.80, core operating EPS of ~$6.65 topped the $6.21 bar, MA and ACA outperformed, and management is being conservative by not banking first-half favorability. The selloff is an overreaction to optics.

Bear view: On any operating measure this was a miss dressed as a beat: operating gain down ~28%, Health Benefits gain down ~43%, MLR up 80bps, and the entire "raise" is a $0.25 baseline nudge plus a windfall being spent away. The reported number is not run-rate.

Our take: The operating beat was real but small (~$0.44), and it was the wrong kind, concentrated in the higher-margin lines while the core deteriorated and the headline leaned on portfolio marks. This is the second straight below-the-line-flattered print; the market is right to discount the headline, and we side with the bear on quality while conceding the bull's point that the underlying franchise is not impaired.

Debate: Is Medicaid actually troughing, or is the margin stuck?

Bull view: The -1.75% floor is holding, July rates are improving, acuity pressure is moderating with "no new stepwise reset," and the market exits will lift the quality of the remaining book; 2026 is the trough and 2027 improves as rates catch trend and actions mature.

Bear view: Better rates that produce zero margin lift mean trend is still outrunning rate, and a company that must exit markets to fix Medicaid economics is admitting pricing alone cannot; the "trough" could prove to be a plateau, and the recovery slope is a promise, not a datapoint.

Our take: This is the crux, and Q2 tilted it toward the bear on slope while leaving the bull's floor intact. The trough level holds, but the evidence for a steep recovery out of it weakened this quarter, not strengthened. We need to see a rate cycle actually move the margin before underwriting the slope, and until then Medicaid is a floor, not an engine.

Debate: With the re-rate round-tripped, is the risk/reward still favorable?

Bull view: At ~13.4x a ≥$29.12 2027 number, with CMS cleared, MA inflecting, a near-record commercial pipeline, and the baseline still rising, the stock is cheap again after an overdone selloff; the re-rate toward mid-teens has further to run and the 8.5% drop is an entry.

Bear view: The easy recovery money was made on the spring run to $426; with the operating margin compressing, Medicaid stuck, and the 2027 bridge leaning on windfall-funded capability spend and portfolio contraction, the multiple stays range-bound until 2027 EPS actually shows up, and there is downside if the Medicaid slope disappoints.

Our take: After the round-trip to $390, the stock trades at our fair value rather than below it, so the asymmetry that justified Outperform at $328 is gone. The recovery is intact enough to preclude a bearish call and priced fully enough to preclude a bullish one. That is the definition of a Hold: own it for the diversified 2027 bridge and the ~1.8% yield, but there is no longer a valuation cushion to underwrite the quality and Medicaid-slope risks the quarter surfaced.

Model Update Needed

Valuation framework: We move to a fair-value range of roughly $375-$410, about 13-14x a ~$29.12 2027 earnings power (≥12% off the ≥$26.00 baseline), toward the lower half of ELV's historical mid-teens multiple to reflect the compressing operating margin, the stalled Medicaid slope, and two consecutive low-quality beats, partly offset by the removal of the CMS overhang. Against the $390.33 close, the ~$392 midpoint implies roughly flat price return over our 12-month horizon, plus the ~1.8% dividend yield. The stock has round-tripped our prior $380-410 range: it re-rated ~30% into the print and gave it back on the day. The re-rate we underwrote at the Q4 upgrade has been paid; from here the multiple needs 2027 to deliver the ≥12%, and specifically needs the Medicaid margin to actually inflect, before it can push toward the mid-teens again. That is a "prove it" setup, not a "buy the dip" one.

Thesis Scorecard Post-Earnings

Overall: Thesis weakened. The recovery's diversified legs (MA, commercial, Carelon, higher baseline) are intact and the biggest tail risk (CMS) cleared cleanly, but earnings quality deteriorated for a second straight quarter, operating margins compressed, and the Medicaid recovery slope, a load-bearing assumption of the multi-year case, is newly in doubt after better rates failed to lift the margin and management opened a market-exit program. The floor of the thesis holds; the slope and the quality do not.

Action: Downgrade to Hold from Outperform. Our Q4 2025 upgrade underwrote a quantified trough at a washed-out ~12x with an explicit ≥12% 2027 algorithm, and it worked: the stock re-rated ~30% to a 52-week high, blowing through our $380-410 fair value. After the 8.5% round-trip to $390.33 the stock sits at fair value, the beat quality has weakened, and the Medicaid slope is in question, so the asymmetry that justified Outperform is gone. We do not sell, the diversified 2027 bridge, the MA inflection, the cleared CMS overhang, and the ~1.8% yield are reasons to own it, but we step to the sidelines rather than chase. The path back to Outperform is specific: a genuine Medicaid margin inflection on a rate cycle, an operating-margin stabilization that ends the below-the-line dependence, or a materially lower entry price. The path to Underperform is a Medicaid slope that flattens into 2027 and stalls the ≥12% algorithm.